• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Articles published by Tempus

    Tempus Receives U.S. FDA 510(k) Clearance for Tempus ECG-AF, an AI-based Algorithm that Identifies Patients at Increased Risk of AFib
    From Tempus
    Via Business Wire
    Tickers TEM
    Tempus Announces Collaboration with United Therapeutics to Study Use of AI to Detect Patients at Risk for Pulmonary Hypertension
    From Tempus
    Via Business Wire
    Tempus Introduces New HER2 & FOLR1 Testing Solutions to Support Personalized Patient Care
    From Tempus
    Via Business Wire
    Tempus Announces Expansion of Collaboration with AstraZeneca to Leverage Tempus Next to Support Guideline-directed Biomarker Testing in NSCLC
    From Tempus
    Via Business Wire
    Tempus Announces the Clinical Launch of its MRD Testing Portfolio
    From Tempus
    Via Business Wire
    Tempus Introduces its AI-enabled Care Pathway Intelligence Platform, Tempus Next
    From Tempus
    Via Business Wire
    Tempus Releases New Data at AACR Showcasing Ways to Analyze Multimodal Data to Highlight Potential Therapeutic Routes for HER2-Directed Antibody-Drug Conjugates in Several Tumor Types
    From Tempus
    Via Business Wire
    Tempus Introduces Workspaces into its Lens Data Analytics Platform
    From Tempus
    Via Business Wire
    Tempus Announces 18 Abstracts Accepted For Presentation at the American Association for Cancer Research Annual Meeting 2024
    From Tempus
    Via Business Wire
    Tempus Contributes De-Identified Cancer Data to Planned Data Enclave
    From Tempus
    Via Business Wire
    Tempus Expanding Access to its Next-Generation Sequencing Tests as an In-Network Provider for Cigna
    From Tempus
    Via Business Wire
    Tempus Introduces AI-enabled Assistant, Tempus One, Into Lens Data Analytics Platform to Accelerate Research
    From Tempus
    Via Business Wire
    Tempus is Now an In-Network Provider for Humana, Expanding Access to its Next-Generation Sequencing Tests
    From Tempus
    Via Business Wire
    Tempus Introduces xM to Assess Minimal Residual Disease (MRD) in Patients with Colorectal Cancer (CRC) for Research Use Only
    From Tempus
    Via Business Wire
    Tempus Announces Medicare Coverage for Tempus|xT Across Solid Tumor and Hematologic Malignancies
    From Tempus
    Via Business Wire
    Tempus Announces Research Collaboration with Bristol Myers Squibb to Apply Multimodal AI Approaches
    From Tempus
    Via Business Wire
    Tempus Announces New ctDNA Assay, xF Monitor
    From Tempus
    Via Business Wire
    FDA Grants Breakthrough Device Designation To Tempus’ HLA-LOH Companion Diagnostic Test
    From Tempus
    Via Business Wire
    Tempus Announces the GEMINI Non-Small Cell Lung Cancer Study
    From Tempus
    Via Business Wire
    Tempus Announces Companion Diagnostic Collaboration with TScan Therapeutics
    From Tempus
    Via Business Wire
    Tempus Announces Broad Launch of Tempus One
    From Tempus
    Via Business Wire
    Tempus Announces Dr. Ned Sharpless as a Senior Strategic Advisor
    From Tempus
    Via Business Wire
    Tempus Receives U.S. FDA Approval for xT CDx, a NGS-Based In Vitro Diagnostic Device
    From Tempus
    Via Business Wire
    Tempus Announces New Strategic Collaboration with Pfizer to Advance Oncology Therapeutic Development
    From Tempus
    Via Business Wire
    Tempus Announces Prospective Study for Biomarker Discovery in Small Cell Lung Cancer
    From Tempus
    Via Business Wire
    Tickers AZN
    Tempus Launches First Cardiology Prospective Study for Its AI-Enabled Predictive Tests
    From Tempus
    Via Business Wire
    Tempus Announces Real-World Data-Driven Program to Accelerate Precision Oncology Research
    From Tempus
    Via Business Wire
    Tempus Announces Companion Diagnostic Collaboration with Kartos Therapeutics
    From Tempus
    Via Business Wire
    Tempus Announces Three Abstracts Accepted For Presentation at the European Society for Medical Oncology Congress 2022
    From Tempus
    Via Business Wire
    Tempus Announces Sequencing Collaboration With Lilly to Expand Access to Genomic Testing
    From Tempus
    Via Business Wire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.